China Biologic Products (CBPO) Announces Acquisition of Full Guizhou Taibang Ownership
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Stocks and yen struggle as tech troubles weigh
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil steady as US demand concerns balance Middle East conflict risks
- Yen hits fresh 34-year lows against dollar ahead of BOJ meeting
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Crude Inventory Declined 6.4 Million Barrels Last Week
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
China Biologic Acquires Full Ownership of Guizhou Taibang
October 26, 2016 8:30 AM EDTBEIJING, Oct. 26, 2016 /PRNewswire/ -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that Guizhou Taibang Biological Products Co. Ltd. ("Guizhou Taibang") completed the requisite legal and administrative procedures, through which two former minority shareholders, holding a combined 15.3% equity interest in Guizhou Taibang, Â withdrew their respective capital contributions in Guizhou Taibang for an aggregate consideration of RMB415.0 million (approximately US$62.1 million) pursuant to an agreement dated July 31, 2016, a summary of which was filed as an exhibit to the... More
